The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Launched by WUHAN UNIVERSITY · May 15, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at a new type of radiation therapy called involved-site radiotherapy (ISRT) for patients with advanced-stage Diffuse Large B-cell Lymphoma (DLBCL), a type of blood cancer. The goal is to see if ISRT is as effective as the standard radiation treatment (involved-field radiotherapy or IFRT) while causing fewer side effects. Patients who are newly diagnosed or have recurrent DLBCL, aged between 18 and 65, and in good overall health may be eligible to participate.

Participants in the trial will receive treatment after chemotherapy, which is the typical first step for this type of cancer. They will be closely monitored for how well the treatment works and for any side effects. It’s important to know that patients can choose to leave the study at any time if they wish. The trial aims to find a better way to manage DLBCL and improve patients' quality of life during treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Both male and female aged range from 18 years to 65 years.
• • Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1.
• • All patients had histologically confirmed Diffuse large B-cell lymphoma.
• • Advanced-stage DLBCL patients at newly diagnosed or recurrent without RT in initial management.
• • Adequate organ function.
• • Negative pregnancy test.
• • Signed informed consent document on file.
• Exclusion Criteria:
• • Woman who were pregnant or lactating.
• • With severe local infection or general infective disease.
• • Primary lymphoma in special organ including cuticula, center never system, gastrointestinal tract, testicle, and lung.
• • With other second primary malignancy except cutaneum carcinoma.
• • Being or planning to participate in other study.
• • Any patient who in the opinion of the investigator should not participate in the study.
• Withdrawal Criteria:
• • Patient are free to withdrawal completely from the study at any time upon request.
• • Patient in the study may be stopped with the patient agreement at any time at the discretion of investigator.
• • In-field progression on irradiation ongoing.
• • Poor tolerability adverse events in the period of chemotherapy or irradiation after enrolled in the study.